PubMed · 9418365
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
R Hershkovitz, M Mazor. 1997-10-02. [Hormonal changes in term and preterm delivery].. https://pubmed.ncbi.nlm.nih.gov/9418365/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
UNLABELLED: Excellent long-term outcomes of transplant patients let many female liver-recipients experience perimenopausal problems. This study assessed menstrual patterns and sex hormone profiles in women of perimenopausal age who experienced end-stage liver failure treated by transplantation (OLT). MATERIALS AND METHODS: Menstrual patterns, sex hormone profiles, and biochemical parameters of liver function were analyzed before and after OLT in 13 liver-transplanted patients of perimenopausal age. Nineteen healthy perimenopausal women served as controls. RESULTS: The most common abnormality of the menstrual cycle observed in the study group was secondary amenorrhea, which affected six liver-transplanted women. Three months after OLT amenorrhea was still observed in six patients, regular menstrual cycles in six and irregular bleeding in one graft recipient. One year after transplantation regular menstruations were noted in four, irregular bleeding in four, and secondary amenorrhea in five liver-transplanted women. Similar levels of follicle stimulating hormone, luteinizing hormone, prolactin, progesterone and testosterone as well as lower levels of estradiol and DHEA-sulfate were observed in patients with liver failure, both before and after grafting, compared with healthy women. After OLT E2 levels increased from 32.05 +/- 18.04 to 49.12 +/- 22.21. CONCLUSIONS: One year after OLT disturbances in menstrual patterns affect most (69%) perimenopausal female liver recipients. Both before and after OLT significantly lower levels of estradiol and DHEA-S were observed in transplanted patients compared with healthy controls. Hormonal therapy of amenorrhea or irregular menstruations may be required in that group of patients.
UNLABELLED: The aim of our study was to investigate if there is any significant relationship between adrenal steroid hormone dehydroepiandrosterone-sulphate (DHEAS) and insulin resistance, as there are some previous signs in the literature suggesting such relationship but the results are not conclusive. METHODS: In our study participated 50 obese women and 20 obese men both with BMI over 27 kg/m2. Insulin resistance was calculated using HOMA insulin resistance index (HOMA-IR) that is based on fasting glycaemia and basal insulin levels. RESULTS: The negative correlation between DHEAS and HOMA-IR was found in the whole group of obese women but close behind statistical significance (r = -0.27, p = 0.055). But the group of obese women does not seem to be homogenous in correlation between DHEAS and insulin resistance. The significant negative correlation between DHEAS and insulin resistance was found in the subgroup (n = 21) of obese type 2 diabetic women (r = -0.55, p = 0.01) but no correlation was found in the subgroup (n = 29) of obese non-diabetic women (r = -0.06, p = 0.77). The relationship between DHEAS and glycaemia homeostasis was also confirmed by significant negative correlation between DHEAS and glycated haemoglobin (HbA1c) both in the subgroup of type 2 diabetic women (r = -0.51, p = 0.03) and in the subgroup of non-diabetic women (r = -0.70, p = 0.001). There was not found any significant correlation between DHEAS and insulin resistance neither in the whole group (n = 20) of obese men (r = 0.04, p = 0.87) nor in the subgroup (n = 11) of obese type 2 diabetic men (r = 0.55, p = 0.08) or in the subgroup (n = 9) of obese non-diabetic men (r = -0.42, p = 0.26). CONCLUSIONS: Significant negative correlation between DHEAS and HOMA-IR was found in the group of obese type 2 diabetic women but not in obese non-diabetic women suggesting that low DHEAS level might be connected to the development of insulin resistance and type 2 diabetes mellitus in obese women.
AIM: The purpose of this study was to investigate the effect of soy supplementation with isoflavones on plasma hormone levels in postmenopausal women. METHODS: 16 postmenopausal women (mean age 56.21 +/- 5.01 years) were assigned to 24 weeks of dietary soy supplementation. A defined soy protein amount per day (20 g) with a low dosage of isoflavones (20 mg) was used. Plasma samples were analyzed for estradiol, FSH, LH, prolactin, testosterone and DHEAS. RESULTS: After 24 weeks of soy supplementation, plasma levels of estradiol did not increase. Gonadotropins, prolactin and the measured plasma androgens remained unchanged. We did not see any significant treatment effects. CONCLUSIONS: In the postmenopausal hypoestrogenic situation, soy protein consumption with low isoflavones does not influence endogenous hormone levels of estradiol and gonadotropins.